Table 1.
Baseline characteristics in the SMART drug conservation arm
| Virological Suppression arm | Drug Conservation arm | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| HBV a (n=62) |
HCV (n=385) |
Non- HBV/HCV (n=2305) |
Total (n=2752) |
HBV b (n=72) |
HCV (n=411) |
Non- HBV/HCV (n=2237) |
Total (n=2720) |
||
| Median age (IQR) (years) | 45 (38–49) | 46 (41–50) | 43 (37–50) | 44 (38–50) | 41 (38–49) | 46 (40–51) | 43 (37–50) | 43 (37–50) | |
| HIV transmission category | |||||||||
| - MSM sex contact (%) | 48 | 27 | 52 | 48 | 60 | 27 | 55 | 51 | |
| - Heterosexual sex contact(%) | 44 | 42 | 46 | 46 | 42 | 45 | 44 | 44 | |
| - IDU (%) | 6 | 57 | 2 | 10 | 8 | 53 | 2 | 10 | |
| - Other or unknown (%) | 8 | 11 | 9 | 9 | 6 | 7 | 8 | 8 | |
| Median (IQR) baseline CD4 (/mm3) | 570 (449–677) |
566 (459–726) |
605 (467–798) |
598 (465–789) |
556 430–708) |
607 (466–812) |
596 (468–792) |
597 (467–791) |
|
| Median nadir CD4 (/mm3) | 245 (120–382) |
250 (150–389) |
250 (160–354) |
250 (157–358) |
207 (93–285) |
264 (155–360) |
250 (154–359) |
250 (152–358) |
|
| Baseline HIV RNA ≤400 copies/ml (%) | 63 | 61 | 73 | 71 | 72 | 68 | 72 | 72 | |
| Prior AIDS (%) | 24 | 28 | 22 | 23 | 29 | 27 | 25 | 25 | |
| ART at entry (%) | 74 | 78 | 85 | 84 | 79 | 82 | 85 | 84 | |
| - 3TC, not TDF (%) | 40 | 56 | 58 | 57 | 42 | 55 | 57 | 56 | |
| - TDF, not 3TC (%) | 10 | 4 | 5 | 5 | 8 | 6 | 6 | 6 | |
| - 3TC/FTC and TDF | 18 | 11 | 12 | 12 | 17 | 13 | 12 | 12 | |
| HBeAg / ant-HBe (%) c | 59/36 | 50/45 | |||||||
| HBV DNA detectable at entry (%) d | 53 | 55 | |||||||
| Median (IQR) log10 HBV DNA (IU/ml) e | 7.4 (4.2– 8.4) |
8.1 (3.4– 8.5) |
|||||||
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; MSM, men who have sex with men; TDF, tenofovir; 3TC, lamivudine; FTC, emtricitabine; ART, antirretroviral therapy.
a
Includes 8 participants with HBV/HCV coinfection.
b
Includes 6 participants with HBV/HCV coinfection.
c
Out of 66 DC and 55 VS with stored specimens available.
d
Out of 66 DC and 55 VS with stored specimens available.
e
Out of 36 DC and 29 VS with detectable HBV DNA